



You are entering a medical section of the Pfizer Landing Page. All materials presented here are informative and they are not intended to be promotional.

Pfizer Oral Presentations

Circulating Tumor DNA: A Versatile Analyte to Guide the Care of Patients With Lung Cancer

Friday, June 4 9:00 AM – 10:15 AM EDT

Lorlatinib Abstract 9011
Early circulating tumor (ct)DNA dynamics and efficacy of lorlatinib: Analysis from the CROWN study
Soo RA

Breast Cancer – Metastatic

Saturday, June 5 1:30 PM – 4:30 PM EDT

Palbociclib Abstract 1000
Overall survival (OS) with palbociclib (PAL) + fulvestrant (FUL) in women with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC): Updated analyses from PALOMA-3
Cristofanilli M

Breast Cancer – Local/Regional/Adjuvant

Sunday, June 6 8:00 AM – 11:00 AM EDT

Talazoparib Abstract 505
Neoadjuvant talazoparib in patients with germline *BRCA1/2* (*gBRCA1/2*) mutation-positive, early HER2-negative breast cancer (BC): Results of a phase 2 study
Litton J

Melanoma/Skin Cancers

Sunday, June 6 8:00 AM – 11:00 AM EDT

Encorafenib/Binimetinib Abstract 9507
5-year overall survival (OS) in COLUMBUS: A randomized phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients (pts) with BRAF V600-mutant melanoma
Dummer R

Hematologic Malignancies – Plasma Cell Dyscrasia

Tuesday, June 8 8:00 AM – 11:00 AM EDT

Elranatamab (PF-06863135) Abstract 8006
Efficacy and safety of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MM)
Bahlis N

Pfizer Poster Discussions

All Poster and Poster Discussion sessions will be available to attendees for on-demand viewing beginning Friday, June 4. Attendees can view individual poster presentations at their leisure during and after the meeting.

Gastrointestinal Cancer—Colorectal and Anal

Friday, June 4 9:00 AM – 10:00 AM EDT

Encorafenib/Cetuximab Abstract 3513
Molecular correlates of clinical benefit in previously treated patients (pts) with BRAF V600E-mutant metastatic colorectal cancer (mCRC) from the BEACON study
Kopetz S

Genitourinary Cancer – Kidney and Bladder

Friday, June 4 9:00 AM – 10:00 AM EDT

Avelumab Abstract 4514
Outcomes of patients who progressed while receiving avelumab + axitinib (A + Ax) and received subsequent treatment (Tx) in JAVELIN Renal 101
Albiges L

Gynecologic Cancer

Friday, June 4 9:00 AM – 10:00 AM EDT

Binimetinib Abstract 5519
Molecular results and potential biomarkers identified from MILO/ENGOT-ov11 phase 3 study of binimetinib versus physicians choice of chemotherapy (PCC) in recurrent low-grade serous ovarian cancer (LGSOC)
Grisham R

Hematologic Malignancies – Leukemia, Myelodysplastic Syndromes, and Allotransplant

Friday, June 4 9:00 AM – 10:00 AM EDT

AML Abstract 7016
A mixed methods study exploring the role of perceived side effects on treatment decision-making in older adults with acute myeloid leukemia (AML)
Maze D

Bosutinib Abstract 7009
Second-line bosutinib (BOS) for patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML): Final 10-year results of a phase 1/2 study
Gambacorti-Passerini C

Inotuzumab Abstract 7017
A registry-based, observational safety study of inotuzumab ozogamicin (InO) treatment in patients (pts) with B-cell precursor acute lymphoblastic leukemia (ALL) who proceeded to hematopoietic stem cell transplant (HSCT)
de Lima C

Melanoma/Skin Cancers

Friday, June 4 9:00 AM – 10:00 AM EDT

Avelumab Abstract 9517
Avelumab in patients with previously treated Merkel cell carcinoma (JAVELIN Merkel 200): Updated overall survival data after more than five years of follow-up
Nghiem PT

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Sunday, June 6 9:00 AM – 10:00 AM EDT

PF-06939999 (PRMT5) Abstract 3019
PF-06939999, a potent and selective PRMT5 inhibitor, in patients with advanced or metastatic solid tumors: A phase 1 dose escalation study
Rodon Ahnert J

Pfizer ePosters

All Poster and Poster Discussion sessions will be available to attendees for on-demand viewing beginning Friday, June 4. Attendees can view individual poster presentations at their leisure during and after the meeting.

Breast Cancer – Local/Regional/Adjuvant

Talazoparib 554
Neoadjuvant talazoparib (TALA) in patients (pts) with germline *BRCA1/2* (*gBRCA1/2*) mutation-positive, early HER2-negative breast cancer (BC): Exploration of tumor *BRCA* mutational status and zygosity and overall mutational landscape in a phase 2 study
Telli M

Breast Cancer – Metastatic

Palbociclib 1071
Real-world quality of life (QoL) in black, indigenous and people of color (BIPOC) treated with palbociclib (PAL) and endocrine therapy for hormone receptor–positive (HR+)/human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC): A subgroup analysis from POLARIS
Rocque GB

Talazoparib 1029
Characterization of long-term responders following treatment with talazoparib (TALA) or physician's choice of chemotherapy (PCT) in the phase 3 EMBRACA trial
Etti J

Talazoparib 1090
Clinical outcomes in patients (pts) with a history of central nervous system (CNS) metastases receiving talazoparib (TALA) or physician's choice of chemotherapy (PCT) in the phase 3 EMBRACA trial
Litton J

Developmental Therapeutics – Immunotherapy

PF-06753512 (VBIR-1) 2612
First-in-human, phase I study of PF-06753512, a vaccine-based immunotherapy regimen (PrCa VBIR), in non-metastatic hormone-sensitive biochemical relapse (nmBCR) and metastatic castration-resistant prostate cancer (mCRPC)
Autio KA

PF-07265807 (ARRAY-067) TPS671
Trials in progress: A phase 1, open-label, dose-escalation, pharmacokinetic, safety and tolerability study of the selective TAM kinase inhibitor PF-07265807 in patients with advanced or metastatic solid tumors
Subbiah V

Developmental Therapeutics – Molecularly Targeted Agents and Tumor Biology

PF-07284890 (ARRAY-461) TPS3152
Trial in progress: Phase 1a/b study of PF-07284890 (brain-penetrant BRAF inhibitor) with/without binimetinib in patients with BRAF V600-mutant solid tumors
Subbiah V

Gastrointestinal Cancer – Colorectal and Anal

Encorafenib/Cetuximab 3583
Overall survival (OS) with encorafenib (enco) + cetuximab (cetux) in BEACON CRC: Effect of prior therapy for BRAF V600E-mutant metastatic colorectal cancer (mCRC)
Kopetz S

Encorafenib/Cetuximab TPS3619
BREAKWATER: A randomized phase 3 study of encorafenib (enco) + cetuximab (cet) with or without chemotherapy for the first-line treatment of BRAF V600E-mutant metastatic colorectal cancer (mCRC)
Kopetz S

Genitourinary Cancer – Kidney and Bladder

Avelumab 4525
Avelumab first-line (1L) maintenance plus best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma (UC): Analysis of time to end of next-line therapy in JAVELIN Bladder 100
Grivas P

Avelumab 4527
Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC) in the JAVELIN Bladder 100 trial: Subgroup analysis by duration of treatment-free interval (TFI) from end of chemotherapy to start of maintenance
Sridhar SS

Avelumab 4547
Integrating peripheral biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A + Ax) vs sunitinib (S) in advanced renal cell carcinoma (aRCC)
Choueiri TK

Avelumab 4548
Association of C-reactive protein (CRP) with efficacy of avelumab + axitinib (A + Ax) in advanced renal cell carcinoma (aRCC): Long-term follow-up results from JAVELIN Renal 101
Tomita Y

Avelumab 4549
Association between neutrophil-to-eosinophil ratio (NER) and efficacy outcomes in the JAVELIN Renal 101 study
Tucker M

Avelumab 4574
Efficacy of avelumab + axitinib (A + Ax) vs sunitinib (S) by IMDC risk group in advanced renal cell carcinoma (aRCC): Extended follow-up results from JAVELIN Renal 101
Haanen J

Genitourinary Cancer – Prostate, Testicular, and Penile

Enzalutamide 5071
The efficacy of enzalutamide (ENZA) plus androgen deprivation therapy (ADT) on bone oligometastatic hormone-sensitive prostate cancer: A post hoc analysis of ARCHES
Armstrong AJ

Enzalutamide 5072
Real-world first-line (1L) treatment patterns in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) in a U.S. health insurance database
Swami U

Enzalutamide 5073
Real-world utilization of advanced therapies and racial disparity among patients with metastatic castration-sensitive prostate cancer (mCSPC): A Medicare database analysis
Freedland SJ

Enzalutamide 5074
Real-world treatment patterns among patients diagnosed with metastatic castration-sensitive prostate cancer (mCSPC) in community oncology settings
George DJ

Relugolix 5075
Impact of age on efficacy and safety of relugolix: A subgroup analysis from the randomized, phase 3 HERO study vs leuprolide in men with advanced prostate cancer
Cookson M

Talazoparib 5047
Talazoparib (TALA), an oral poly(ADP-ribose) polymerase (PARP) inhibitor for men with metastatic castration resistant prostate cancer (mCRPC) and DNA damage response (DDR) alterations: Detailed safety analyses from TALAPRO-1 trial
Mehra N

Talazoparib TPS5089
TALAPRO-2: A phase 3 randomized study of enzalutamide (ENZA) plus talazoparib (TALA) vs placebo in patients with new metastatic castration-resistant prostate cancer (mCRPC)
Agarwal N

Hematologic Malignancies – Leukemia, Myelodysplastic Syndromes, and Allotransplant

Bosutinib 7037
The effect of body mass index on efficacy and safety of bosutinib or imatinib in patients with newly diagnosed chronic myeloid leukemia
Brummendorf T

Bosutinib 7039
Outcomes before and after dose reduction in patients with newly diagnosed chronic myeloid leukemia receiving bosutinib or imatinib
Deininger M

Prevention, Risk Reduction, and Hereditary Cancer

Talazoparib 10598
Impact of race on biomarker testing among HER2- advanced breast cancer (ABC) patients (pts) in the United States: Results from a real-world study
Mahtani R

Publication Only

Bosutinib e19030
Retrospective real-world comparison of clinical and economic burden between first-generation and second-generation tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML)
Russell-Smith TA

Encorafenib/Binimetinib e18778
Real world analysis of BRAF testing rates among patients with mCRC, metastatic melanoma and NSC lung cancer
Edwards M

Encorafenib/Cetuximab e15523
Global BRAF testing practices in metastatic colorectal cancer
Desai J

Palbociclib e13021
Real-world starting dose and outcomes of palbociclib plus an aromatase inhibitor for metastatic breast cancer
Patt D